One of the aims of the programmes is to monitor the quality of the finished products in all part of the distribution chain throughout the authorised shelf-life, to check their compliance with the approved specifications. The staff that has the responsibility to take the samples (normally Inspectors of the National Authorities), whenever possible will endeavour to have access directly to the products available in the pharmacies (community or hospitals pharmacies) - or at the wholesalers.
The exact number of units (tablets, vials, bottles, etc.) is decided by EDQM on the basis of the parameters that need to be analysed. Samples are normally taken from 3 different countries of the European Economic Area.
A voucher system has been implemented, and vouchers are provided (through EDQM) by the MAH to the Inspectors. The vouchers are exchanged at the point of sampling for the products; the vouchers will then entitle to obtain from the manufacturer a quantity of product that corresponds to the units sampled.
Testing is carried out in the laboratories of the OMCL network. Normally one laboratory is involved in the testing of chemical products and two for biological products. The laboratories are chosen on the basis of their competency, expertise and equipment.
Currently yes. Only the human medicines that are subject to Official Batch Release (e.g. blood products and vaccines) are excluded from this exercise - and, of course, those products that have still to be launched, and that are therefore not available on the European market. In the future not all CAPs will undergo testing as a risk based approach to the selection of products will be implemented.
Testing reports are prepared by the EDQM and are sent on an on-going basis to the European Medicines Agency. Each report is forwarded by the European Medicines Agency to the product's Rapporteur and the Co-Rapporteur who, on the basis of the results, will decide on the action(s) to be taken. A copy of the report is sent to the marketing authorisation holder for comments.
In the most serious cases this could lead to the withdrawal of the product from the market. In most of the cases, however, the problems identified during the testing can be dealt with by further investigations (e.g. Inspection at a manufacturing site, seeking clarification from the Marketing Authorisation Holder). A specific European Medicines Agency procedure is implemented to deal with products whose testing has highlighted quality problems or technical issues.
Every year, the Marketing Authorisation Holders pay to the European Medicines Agency an annual fee to maintain the marketing authorisation. Part of these fees is used for the implementation of the programmes.
A procedure for a risk based approach to the selection of products and parameters tested is currently under development. At present some of those products for which quality or techical issues have been identified can be submitted, on the advice of the Scientific Committees to a re-testing (sometime limited to specific parameters).